ArticleMolecular and clinical oncology2026
Differentiation therapy targeting indoleamine 2,3-dioxygenase 1 in glioblastoma cells
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma cells strongly express the tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which is important in enabling immune evasion. Notably, glioma stem-like cells (GSCs) express higher levels of IDO1 than differentiated glioblastoma cells (DGCs); therefore, it was hypothesized that IDO1 inhibition in GSCs may induce differentiation. The present study used the glioblastoma cell line U-87MG, and newly established GSC lines 0125-GSC and 0222-GSC. A model GSC line, Rev-U-87MG, was created by culturing U-87MG in serum-free medium. Rev-U-87MG-IDO(-) was generated by continuous treatment with an IDO1 inhibitor. The DGC lines 0125-DGC and 0222-DGC were derived by culturing 0125-GSC and 0222-GSC in serum-containing medium. IDO1-inhibited GSC lines 0125-GSC-IDO(-) and 0222-GSC-IDO(-) were generated by continuous IDO1 inhibitor exposure. The expression levels of IDO1 and stem cell markers (Nestin, Nanog and Sox2) were measured by western blotting, and temozolomide sensitivity was evaluated by cell counting. Notably, U-87MG, 0125-DGC and 0222-DGC adhered without sphere formation. By contrast, Rev-U-87MG, 0125-GSC and 0222-GSC formed spheres, whereas IDO1-inhibited cells showed partial adhesion with reduced sphere formation. IDO1 and stem cell marker expression were reduced in all IDO1-inhibited cell lines. Rev-U-87MG exhibited decreased temozolomide sensitivity compared with U-87MG, whereas Rev-U-87MG-IDO(-) showed increased sensitivity. Similarly, 0125-DGC and 0222-DGC were more sensitive than their parent GSC lines, and 0125-GSC-IDO(-) and 0222-GSC-IDO(-) also exhibited enhanced drug sensitivity compared with their parent GSC lines at multiple concentrations. These findings suggest that IDO1 inhibition may induce the differentiation of GSCs and reduce their resistance to temozolomide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.